Advert - Otsuka Pharmaceuticals UK Ltd – Case AUTH/3751/3/23

• Date posted
  24 October 2024
• Sanction
  Advertisement,
• Case number/s
  AUTH/3751/3/23 - Ex-employee v Otsuka

For failure to include important information in a healthcare professionals educational guide, that treatment with Jinarc (tolvaptan) should be discontinued if renal insufficiency progresses to CKD stage 5, which could potentially impact patient safety, Otsuka was ruled in breach of the following clauses of the 2021 Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Providing misleading information